---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-115745"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2026-10-14T12:10:32+00:00"
generated_at: "2026-10-14T12:15:05.983333+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MaxCyte preliminary Q3 core revenue ~$8.1M, up 26% YoY; raises FY2026 revenue guidance to ~$34M

## Summary
- Q3 2026 preliminary core business revenue ~$8.1M, up 26% YoY; SPL Program-related revenue over $1.0M, including a $1.0M milestone received in Q3.
- FY2026 revenue guidance raised to ~$34M from prior $30M-$32M: core business ~$28M (prior $25M-$27M) and SPL Program ~$6M (prior ~$5M).
- SPL guidance includes ~$4M of milestone payments and ~$2M of commercial royalties; this was MaxCyte's second SPL milestone of 2026.
- CEO Maher Masoud cites accelerated instrument purchasing from a large customer pulled forward from Q4; core business up ~15% YoY in H2 2026.
- Royalty revenue and full results due Nov 10, 2026; two SPL-partner pivotal trials have potential approval as early as next year.

## SEC filing metadata
- accession: 0001104659-26-115745
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2026-10-14T12:10:32+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000110465926115745/0001104659-26-115745-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000110465926115745/tm2627568d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-115745
- JSON: https://secwatch.observer/filing/0001104659-26-115745.json
- Plain text: https://secwatch.observer/filing/0001104659-26-115745.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.